WB, IHC-P, ChIP
H M R Mk
Endogenous
35
Rabbit IgG
#O95931
23492
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunohistochemistry (Paraffin) | 1:400 - 1:1600 |
| Chromatin IP | 1:50 |
Storage
Specificity / Sensitivity
Species Reactivity:
Human, Mouse, Rat, Monkey
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human CBX7 protein.
Background
The polycomb group (PcG) proteins contribute to the maintenance of cell identity, stem cell self-renewal, cell cycle regulation, and oncogenesis by maintaining the silenced state of genes that promote cell lineage specification, cell death, and cell-cycle arrest (1-4). PcG proteins exist in two complexes that cooperate to maintain long-term gene silencing through epigenetic chromatin modifications. The first complex, EED-EZH2, is recruited to genes by DNA-binding transcription factors and methylates histone H3 on Lys27. This histone methyltransferase activity requires the Ezh2, Eed, and Suz12 subunits of the complex (5). Histone H3 methylation at Lys27 facilitates the recruitment of the second complex, PRC1, which ubiquitinylates histone H2A on Lys119 (6). Chromobox protein homolog 7 (CBX7) is a component of the PRC1 complex that binds to the H3K27me3 mark through its N-terminal chromodomain to facilitate transcriptional repression (7). CBX7 is believed to promote stem cell self-renewal via repression of differentiation-specific genes, in contrast to other CBX proteins that promote lineage commitment (8-10). CBX7 also plays a complex role in cancer, being described as either a tumor suppressor or proto-oncogene, depending on the cellular context and tissue type (7). For instance, CBX7 has been reported as an oncogene in follicular lymphoma and gastric cancer through repression of the INK4A/ARF tumor suppressor locus (11,12). In contrast, CBX7 functions as a tumor suppressor by negatively regulating CCNE1 expression in human lung carcinoma and glioma (13,14). Decreased CBX7 levels have also been correlated with increased malignancy and poor prognosis in other cancer types, including thyroid, bladder, pancreatic, breast, and colon carcinomas, suggesting a potential use for CBX7 as a prognostic biomarker (15-20).
- Boyer, L.A. et al. (2006) Nature 441, 349-53.
- Lee, T.I. et al. (2006) Cell 125, 301-13.
- Park, I.K. et al. (2003) Nature 423, 302-5.
- Molofsky, A.V. et al. (2003) Nature 425, 962-7.
- Tavares, L. et al. (2012) Cell 148, 664-78.
- Gao, Z. et al. (2012) Mol Cell 45, 344-56.
- Li, J. et al. (2021) Front Genet 12, 740794.
- Morey, L. et al. (2012) Cell Stem Cell 10, 47-62.
- Klauke, K. et al. (2013) Nat Cell Biol 15, 353-62.
- Geng, Z. and Gao, Z. (2020) Int J Mol Sci 21, 8594. doi: 10.3390/ijms21228594.
- Scott, C.L. et al. (2007) Proc Natl Acad Sci U S A 104, 5389-94.
- Zhang, X.W. et al. (2010) J Exp Clin Cancer Res 29, 114.
- Forzati, F. et al. (2012) J Clin Invest 122, 612-23.
- Yu, T. et al. (2017) Oncotarget 8, 26637-26647.
- Pallante, P. et al. (2008) Cancer Res 68, 6770-8.
- Hinz, S. et al. (2008) Tumour Biol 29, 323-9.
- Karamitopoulou, E. et al. (2010) Eur J Cancer 46, 1438-44.
- Mansueto, G. et al. (2010) Genes Cancer 1, 210-24.
- Pallante, P. et al. (2010) Eur J Cancer 46, 2304-13.
- Yang, Y. et al. (2021) Onco Targets Ther 14, 5477-5492.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
WB: Western Blotting IHC-P: Immunohistochemistry (Paraffin) ChIP: Chromatin IP
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.